No significant differences in clinical outcomes were observed between ABP 654 and ustekinumab reference product in patients with plaque psoriasis, including among patients who transitioned from ...
BMS has previously said it reckons Sotyktu could become a $4 billion seller at its peak, fuelled by head-to-head studies showing it was more effective at treating moderate-to-severe psoriasis than ...
Sep. 26, 2024 — Scientists believe the hormone hepcidin, when produced in the skin, may be the root cause of psoriasis -- a chronic and sometimes debilitating skin disease that affects 2-3% of ...